The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II study of 3'-deoxy-3'-18F fluorothymidine PET/CT (FLT-PET) in the assessment of early response in locally advanced breast cancer (LABC): Preliminary results of ACRIN 6688.
Lale Kostakoglu
Other Remuneration - MITA
Fenghai Duan
No relevant relationships to disclose
Michael O Idowu
No relevant relationships to disclose
Paul R Jolles
No relevant relationships to disclose
Harry Douglas Bear
No relevant relationships to disclose
Mark Muzi
No relevant relationships to disclose
Jean Cormack
No relevant relationships to disclose
Daniel A. Pryma
Honoraria - IBA; Siemens Healthcare Diagnostics
Research Funding - Siemens Healthcare Diagnostics
Jennifer M. Specht
No relevant relationships to disclose
Linda Hovanessian Larsen
No relevant relationships to disclose
John Miliziano
No relevant relationships to disclose
Sharon Mallett
No relevant relationships to disclose
Anthony Frank Shields
Consultant or Advisory Role - Siemens Healthcare Diagnostics
Stock Ownership - Radiology Corporation of America
David A. Mankoff
No relevant relationships to disclose